World Allergy Organ J:全国范围内耳鼻喉科医生对中国过敏性鼻炎诊断和治疗指南的遵行情况调查

2021-07-21 AlexYang MedSci原创

过敏性鼻炎(AR)是全球发病率越来越高的过敏性疾病之一。在中国北方,根据2008年进行的一项基于人口的研究,自我报告的AR患病率在农村地区为19.1%,在城市地区为13.5%,有明显的地域差异。AR并

过敏性鼻炎(AR)是全球发病率越来越高的过敏性疾病之一。在中国北方,根据2008年进行的一项基于人口的研究,自我报告的AR患病率在农村地区为19.1%,在城市地区为13.5%,有明显的地域差异。AR并不危及生命,但足以降低患者的生活质量。遵守临床指南将有助于改善治疗效果。但耳鼻喉科医生的临床实践并不总是与指南一致。

近期,有研究人员阐述了耳鼻喉科医生对过敏性鼻炎(AR)治疗指南的遵守情况,并确定了导致中国临床实践与指南建议不一致的因素

研究人员设计了一个横断面的全国性调查,并通过线上平台进行。研究人员对在中华医学会耳鼻咽喉头颈外科分会注册的耳鼻喉科医生发送了电子邮件,或在各种学术会议上邀请耳鼻喉科医生扫描链接到调查问卷来进行数据收集。

共有2142名耳鼻喉科医生符合条件并完成了调查。其中,64.7%的人有10年以上的工作经验,97.4%的人为本科或以上学历。大约18.3%的参与者在临床实践中严格遵守指南,而73.7%的参与者在指南的基础上根据其临床经验进行了调整。耳鼻喉科医生最关心的是AR药物的疗效、安全性和适用最低年龄,而最不关心的是病人的喜好。关于鼻内类固醇(INS)、白三烯受体拮抗剂(LTRA)和H1-抗组胺药的使用,分别有86.8%、55.7%和51.2%的耳鼻喉科医生遵守了指南建议。教育背景是影响遵守指南和接受INS的一个因素。

耳鼻喉科医生对六个过敏性鼻炎诊断标准使用频率的平均频率得分

综上所述,绝大多数中国的耳鼻喉科医生都遵守了中国现行的AR指南。耳鼻喉科医生的实际管理与指南推荐的管理之间仍然存在差异。耳鼻喉科医生应该更加关注患者的喜好。另外,更高的教育可以提高耳鼻喉科医生对指南的遵守程度。

原始出处:

Lei Cheng, Hua-Bin Li, Ya-Mei Zhang et al. A nationwide survey of otolaryngologists' compliance with Chinese guidelines for diagnosis and treatment of allergic rhinitis. World Allergy Organ J. Jun 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1934931, encodeId=29b41934931b4, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sat Feb 12 06:48:22 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047432, encodeId=ec9c204e432e4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Oct 31 17:48:22 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737008, encodeId=ed621e3700820, content=<a href='/topic/show?id=e4bd8053614' target=_blank style='color:#2F92EE;'>#耳鼻喉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80536, encryptionId=e4bd8053614, topicName=耳鼻喉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91734239731, createdName=ms5236388012055669, createdTime=Thu May 19 04:48:22 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329530, encodeId=0a751329530a7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jul 23 04:48:22 CST 2021, time=2021-07-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1934931, encodeId=29b41934931b4, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sat Feb 12 06:48:22 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047432, encodeId=ec9c204e432e4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Oct 31 17:48:22 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737008, encodeId=ed621e3700820, content=<a href='/topic/show?id=e4bd8053614' target=_blank style='color:#2F92EE;'>#耳鼻喉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80536, encryptionId=e4bd8053614, topicName=耳鼻喉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91734239731, createdName=ms5236388012055669, createdTime=Thu May 19 04:48:22 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329530, encodeId=0a751329530a7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jul 23 04:48:22 CST 2021, time=2021-07-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1934931, encodeId=29b41934931b4, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sat Feb 12 06:48:22 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047432, encodeId=ec9c204e432e4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Oct 31 17:48:22 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737008, encodeId=ed621e3700820, content=<a href='/topic/show?id=e4bd8053614' target=_blank style='color:#2F92EE;'>#耳鼻喉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80536, encryptionId=e4bd8053614, topicName=耳鼻喉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91734239731, createdName=ms5236388012055669, createdTime=Thu May 19 04:48:22 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329530, encodeId=0a751329530a7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jul 23 04:48:22 CST 2021, time=2021-07-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1934931, encodeId=29b41934931b4, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Sat Feb 12 06:48:22 CST 2022, time=2022-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047432, encodeId=ec9c204e432e4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Oct 31 17:48:22 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737008, encodeId=ed621e3700820, content=<a href='/topic/show?id=e4bd8053614' target=_blank style='color:#2F92EE;'>#耳鼻喉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80536, encryptionId=e4bd8053614, topicName=耳鼻喉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91734239731, createdName=ms5236388012055669, createdTime=Thu May 19 04:48:22 CST 2022, time=2022-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329530, encodeId=0a751329530a7, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jul 23 04:48:22 CST 2021, time=2021-07-23, status=1, ipAttribution=)]
    2021-07-23 膀胱癌

相关资讯

Int J Radiat Oncol Biol Phys:放疗不遵守指南会降低局部晚期胰腺癌患者存活率!

未遵循放疗(RT)指南是否会影响局部晚期胰腺癌患者的存活率和毒副作用?

Cancer:男性前列腺癌患者的决策支持

决策支持工具可以改善决策冲突,并引起患者对前列腺癌治疗的偏好。据推测,使用 "个人患者档案-前列腺(P3P)"的男性将更有可能选择与指南一致的治疗。

《基层心血管病综合管理实践指南2020》在京发布

2020年9月12日,由北京高血压防治协会、北京糖尿病防治协会、北京慢性病防治与健康教育研究会、高血压联盟(中国)、中国老年保健协会养老与健康专业委员会、国家老年疾病临床医学研究中心中国老年心血管病防

与你有关!普通门诊费用跨省直接结算指南来了

自2月1日起,包括新增试点在内的27个普通门诊费用跨省直接结算试点省份实现互联互通,启动试运行。

我国首次出台防治性骚扰指南

深圳市出台性骚扰防治指南。